Common denominators in fibrotic lung disease

model of lung

With fibrotic disease being one of our areas of interest, it has been highly interesting to follow the news in the past six months or so around nintedanib. It is one of only two approved drugs for idiopathic pulmonary fibrosis, IPF. IPF continues to be a focus area for drug development. Even though its root […]

2019 Round Up – A Full Year!

With 2019 coming to a close, we’re reflecting on a year filled with activities including: advising clients on their projects, expanding our network, participating in and presenting at international conferences, and establishing a workshop format for project review and strategy conception. Here’s a look at some of our highlights: Initial review Initial review is our […]

TherapeutAix to present at the Anti-Fibrotic Drug Development Summit in Boston

We are proud partners for the 3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) which will take place on November 18-20th in Boston. Keynote speakers for the event include Glenn Rosen from Coherus Biosciences, Lisa Hazelwood from Abbvie, Matthew Breyer from Janssen, Rozsa Schlenker-Herceg from Boehringer-Ingelheim, Tim Johnson from UCB and Zoe Johnson from iOnctura. The […]

TherapeutAix to present at ELRIG Drug Discovery 2019 in Liverpool

Now in its 13th year, Drug Discovery 2019, ELRIG’s flagship conference, will take place at the ACC in Liverpool on the 5-6th November. The conference is one of the largest meetings of life science industry professionals in the UK. The focus of this year’s event is ‘A Look Back to the Future’ which will examine […]

One year round up – what we’ve been up to in our first year

The 1st September 2019 officially marks the one year anniversary of the launch of TherapeutAix – and what an exciting year it’s been! To celebrate the occasion, we’ve taken a look back at what the company has achieved so far. Company launch After months of preparation, we officially launched TherapeutAix on 1st September 2018 along […]

International NASH Day 2019

On International NASH Day 2019 we discuss the mixed outcomes of NASH drug clinical trials and how we believe a platform of evidence can be built to support future NASH drug development. NASH (Nonalcoholic steatohepatitis) is emerging as a major public health issue for the 21st century that affects 7-12% of adults worldwide. It is […]

TherapeutAix adds Immunoconsulting to global R&D Network

We are pleased to announce that we have grown our global R&D Network with the addition of ImmunoConsulting Ltd. ImmunoConsulting, a consulting business that provides assistance to pharmaceutical and academic spin-out companies developing new therapeutic strategies which target components of the immune system across all therapy areas, is the latest company to join our extensive […]

Recent study highlights the challenges in developing treatments for NASH

We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated cirrhosis (F4) due to NASH. Selonsertib has been tested in another study (STELLAR-3) in an earlier stage (F3) of NASH, where it has now been announced that also here, selonsertib failed to meet the primary endpoint of […]

TherapeutAix/Medicines Discovery Catapult session on drug discovery in fibrotic disease at the BOS Basel event in Switzerland

BOS Basel 2019

BOS (Biotech Outsourcing Strategies) Basel 2019 will bring together stakeholders in pharmaceutical R&D outsourcing, who share knowledge, develop skills and build new and existing relationships with those in the field. The event will cover Drug Discovery Outsourcing and Development Stage CMC Outsourcing for both Small Molecules and Biologics. BOS Basel 2019 will take place on […]

TherapeutAix NASH review article is now available online!

At the end of last year, TherapeutAix published an article titled ‘The future R&D landscape in non-alcoholic steatohepatitis’ in Drug Discovery Today. The review aims to give drug discovery teams guidance on navigating the maze of information currently available on NASH and to provide pointers on areas to consider in early research projects. The final […]

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.